Exelixis, Inc. 10-Q Summary: Quarter Ended March 31, 2006
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2006. Exelixis, Inc. is a biotechnology company focused on discovering and developing pharmaceutical products for cancer and other serious diseases. The company operates primarily through internal drug discovery and strategic collaborations with major pharmaceutical partners. As of April 28, 2006, there were 83,925,538 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2006 | Q1 2005 |
|---|---|---|
| Total Revenues | $18.1 million | $12.9 million |
| Net Loss | $(27.1) million | $(27.4) million |
| Net Loss Per Share (Basic/Diluted) | $(0.32) | $(0.36) |
| Operating Cash Flow | $10.0 million | $(32.3) million |
| Cash and Cash Equivalents (Ending) | $140.1 million | $61.4 million |
| Total Assets | $337.6 million | $332.7 million |
| Total Liabilities | $303.1 million | $275.4 million |
| Stockholders' Equity | $14.3 million | $33.5 million |
Debt and Liquidity: The company holds significant debt obligations, including a $30.0 million convertible promissory note due in May 2006 and long-term notes payable totaling approximately $116.3 million (including current and long-term portions). Total cash, cash equivalents, and marketable securities stood at approximately $219.5 million.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 41% to $18.1 million, driven by a $3.1 million increase in license revenue (amortization of upfront payments) and a $0.9 million increase in contract revenue (R&D funding).
- Expense Increases: Research and Development (R&D) expenses rose 20% to $39.9 million, and General and Administrative (G&A) expenses rose 44% to $9.0 million. A significant driver for both was the adoption of SFAS 123R (Share-Based Payment) on January 1, 2006, which added $4.6 million in stock-based compensation expense.
- Cash Flow Improvement: Operating cash flow swung from a use of $32.3 million in Q1 2005 to a provision of $10.0 million in Q1 2006. This was primarily due to $37.5 million in upfront payments received from new collaborations with Bristol-Myers Squibb ($17.5 million) and Sankyo ($20.0 million), which were recorded as deferred revenue rather than immediate income.
- Investing Activities: Net cash provided by investing activities increased to $32.5 million, largely due to proceeds from the sale of investments held by Symphony Evolution, Inc. and maturities of marketable securities.
Guidance, Outlook, and Risks
Collaborations and Pipeline: Exelixis entered into two major new agreements in early 2006:
- Bristol-Myers Squibb (BMS): Collaboration on Liver X Receptor (LXR) therapies. Includes a $17.5 million upfront payment and $10.0 million annual R&D funding for two years.
- Sankyo Company: Collaboration on mineralocorticoid receptor (MR) therapies. Includes a $20.0 million upfront payment and $3.8 million R&D funding over 15 months.
- Financial Covenants: The company must maintain working capital of at least $25.0 million and cash/investments of at least $50.0 million to comply with covenants in its loan agreement with GlaxoSmithKline. As of March 31, 2006, the company was in compliance ($93.9 million working capital; $219.5 million cash/investments).
- Repayment Obligations: The $30.0 million note to Protein Design Labs is due in May 2006. Failure to repay could trigger default.
- Repurchase Options: The company licensed three key compounds (XL647, XL999, XL784) to Symphony Evolution, Inc. (SEI) in exchange for funding. Exelixis retains options to repurchase these assets. If GlaxoSmithKline selects these compounds for development, Exelixis must repurchase them, potentially requiring significant additional capital.
- Accounting Changes: The adoption of SFAS 123R significantly increased reported expenses, though it is a non-cash charge.
Key Facts for Investor Verification
- Verify the company's ability to repay the $30.0 million convertible promissory note due in May 2006 without dilutive equity issuance or new debt.
- Monitor compliance with GlaxoSmithKline financial covenants (minimum $25M working capital and $50M cash/investments) to avoid acceleration of debt.
- Assess the financial impact of potential repurchase obligations for compounds licensed to Symphony Evolution, Inc., especially if GlaxoSmithKline exercises its option to develop them.
- Review the progress of Phase 3 trials for XL119 and Phase 2 trials for XL999 and XL784, as clinical success is critical for future milestone revenues.
- Confirm the sustainability of revenue growth given the heavy reliance on collaboration upfront payments and amortization, rather than product sales.